Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by tdon1229on Dec 17, 2020 4:42pm
174 Views
Post# 32130902

RE:RE:RE:RE:Tidbits from today's presentation

RE:RE:RE:RE:Tidbits from today's presentation

skys1 wrote: He said their burn rate is now down to only $250,000 P/mo. It used to be more than double that. I had read that they had substantially reduced payroll etc because hospitals had pretty much shut treatments down due to the virus. At any rate, they can last a long time with that burn rate, as last time I checked I think they still had $9 million left from the $17 million raise.

 

As stated coming out of the COVID shutdown, all the money remaining was earmarked for the remainder of the NMIBC Phase II trials ... if they open sites in the US, then they pay each site up front for their participation costs ... after, of course, paying the FDA its fees and the costs for for FDA personnel to oversee and follow the trials ... oh, and RDW and his wife will continue to draw down their outsized salaries which will account for about 15% or so of the remaining total.

<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse